(Q38001276)

26 August 2017

title

Systemic therapy for bone metastases (English)

1 reference

26 August 2017

1 reference

Loftus LS

1

1 reference

26 August 2017

Edwards-Bennett S

series ordinal

2

1 reference

26 August 2017

Sokol GH

series ordinal

3

1 reference

26 August 2017

publication date

1 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

19

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

145-153

1 reference

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Mechanisms of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Future treatment of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Development of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

The Molecular Basis of Bisphosphonate Activity: A Preclinical Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Bisphosphonates: preclinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Safety Considerations for Use of Bone-Targeted Agents in Patients With Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Maintaining Bone Health in Prostate Cancer Throughout the Disease Continuum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Zoledronic Acid Use in Patients With Bone Metastases From Renal Cell Carcinoma or Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Therapeutic Options in the Management of Myeloma Bone Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Potential anticancer properties of bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Oral bisphosphonate use and breast cancer incidence in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Use of bisphosphonates and reduced risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Meta-analysis of clodronate and breast cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Breast-cancer adjuvant therapy with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Reports of esophageal cancer with oral bisphosphonate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Exposure to oral bisphosphonates and risk of esophageal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

More on reports of esophageal cancer with oral bisphosphonate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Targeting activated integrin alphavbeta3 with patient-derived antibodies impacts late-stage multiorgan metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

TGF-β signalling-related markers in cancer patients with bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900209

10.1177/107327481201900209

21 January 2018

Identifiers

DOI

0 references

1 reference